ArticleClinical and translational science2026

Challenges in Implementing Revocation of Oncology Drugs Under Conditional Early Approval in Japan: Regulatory Insights From Comparisons With FDA/EMA.

Takahiro Handa et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.